Letourneau JM, Wald K, Sinha N, et al. - Researchers undertook this retrospective analysis to investigate if fertility preservation (FP) with oocyte/embryo cryopreservation is related to disparities in disease-free survival (DFS) among patients aged 18 to 45 who received a diagnosis of invasive breast cancer between 2007 and 2017 and visited a university fertility center for FP consultation prior to cancer treatment. There were 329 women in total, 207 (63%) in the FP group and 122 (37%) in the no FP group. A median follow-up of 43 months revealed similar DFS rates in both groups. Experts also noted a similarity in terms of positive ER status, neoadjuvant chemotherapy, ER-positive DFS, and neoadjuvant chemotherapy DFS among FP and no FP groups. According to the findings, the influence of FP on DFS, at a median follow-up of 43 months, seemed unlikely even in the setting of tumors with positive ER status or management with neoadjuvant chemotherapy (in which the tumor remains in situ during FP).